Skip to main content
IBIO logo

iBio, Inc.

IBIONASDAQHealthcareBiotechnology

$0.71Today:- (-)1Y −38.27%

As of Oct 26, 2026 close

Market cap
$73.57M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.73$3.82
Volume (live)
-
Avg. volume (3M)
833.34K

iBio (IBIO) Cash Flow Statement

In fiscal 2026 (fiscal year ended Jun 30, 2026), iBio used $23.22M of cash in operating activities and spent $578.00K on capital expenditures. That left free cash flow of −$23.80M.

iBio Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for iBio, Inc. (IBIO) - Annual data in millions USD
BreakdownFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Sep 2020Jun 2019Jun 2018Jun 2017
Operating Activities
Net Income-33.04-18.38-24.91-65.01-50.30-23.21-16.44-17.60-16.11-16.14
Depreciation & Amortization1.031.131.251.383.492.412.241.751.711.68
Deferred Income Tax0.000.000.000.000.000.000.000.000.001.61
Stock Based Compensation1.371.532.044.394.381.590.390.240.771.01
Change in Working Capital2.520.48-3.175.873.24-11.150.471.450.090.29
Change in Accounts Receivable-0.070.000.006.10-0.89-10.740.02-0.020.040.31
Change in Inventory0.000.000.00-1.02-3.870.77-0.80-0.100.030.00
Change in Accounts Payable2.221.83-1.49-0.631.240.050.500.290.05-0.26
Change in Other Working Capital-0.08-0.840.03-0.040.21-1.240.751.28-0.030.24
Other Operating Activities-0.08-0.060.0322.946.510.300.000.180.06-1.61
Net Cash from Operating Activities-23.22-15.30-18.55-30.44-37.48-30.06-13.35-13.98-13.48-13.16
Investing Activities
Capital Expenditures-0.58-0.02-0.21-6.43-7.33-5.16-1.15-0.99-1.08-1.59
Acquisitions0.000.000.00-0.690.000.000.000.000.000.00
Purchases of Investments-42.300.000.0010.84-7.12-23.820.000.000.000.00
Sales/Maturities of Investments10.800.000.0010.8413.624.000.000.000.000.00
Other Investing Activities10.880.761.122.60-4.30-1.74-0.080.000.000.00
Net Cash from Investing Activities-32.000.740.917.01-5.13-26.48-1.15-0.99-1.08-1.59
Financing Activities
Debt Repayment-0.770.40-2.039.42-5.83-0.33-1.46-0.20-0.18-0.17
Common Stock Issued3.539.9225.5211.490.0873.620.003.6522.590.00
Common Stock Repurchased0.000.00-0.010.040.050.000.000.000.000.00
Other Financing Activities66.825.950.12-0.02-0.3779.1766.650.000.000.00
Net Cash from Financing Activities103.058.9324.492.30-6.1378.8465.193.4522.41-0.17
Summary
Effect of Forex Changes on Cash-0.020.000.000.03-6.000.000.000.000.000.00
Net Change in Cash47.83-5.636.85-21.09-48.7322.2950.69-11.517.85-14.93
Cash at Beginning of Period8.7914.437.5828.6777.4055.114.4215.938.0923.01
Cash at End of Period56.628.7914.437.5828.6777.4055.114.4215.938.09
Free Cash Flow-23.80-15.32-18.76-36.87-44.81-35.23-14.50-14.97-14.56-14.76
Supplemental Disclosures
Interest Paid-0.210.750.691.052.45----

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About iBio Cash Flow

What is iBio's free cash flow?

iBio had negative free cash flow of $23.80M in fiscal 2026 (fiscal year ended Jun 30, 2026), operating cash flow of −$23.22M minus $578.00K of capital expenditures.

How much does iBio spend on capital expenditures?

iBio spent $578.00K on capital expenditures in fiscal 2026, compared with $16.00K a year earlier.

Does iBio pay dividends or buy back shares?

iBio's cash flow statement for fiscal 2026 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition